Study analysis · JAMA Network Open · 2026
Berberine failed to reduce belly fat or liver fat in a rigorous trial—but it did lower cholesterol and inflammation in certain people.
Taking berberine daily for 6 months did not reduce belly fat or liver fat in people with obesity and fatty liver who don't have diabetes, but it modestly lowered 'bad' cholesterol and inflammation markers.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
Imagine a test where some people get a real medicine and some get a fake pill that looks the same. Nobody knows who got which, not even the doctors. This kind of test is one of the best ways to see if a medicine really works. In this test, the real medicine did not help reduce belly fat or liver fat, but it seemed to lower bad cholesterol and some signs of swelling in the body. However, those good effects need more checking to be sure.
What’s the bottom line?
Researchers tested a natural supplement called berberine in people with obesity and fatty liver but without diabetes. They gave half the group berberine and half a fake pill (placebo) for 6 months. They used CT scans to measure belly fat and liver fat.
How strong is this study?
This study was done carefully: a lot of people took part, the groups were made to be similar, and the people running the test didn't know who got what. This makes the results more trustworthy. But some of the findings (like the cholesterol changes) weren't the main focus, so we should be a little careful until more studies confirm them.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
95 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=337)+16.3/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 578 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. For the primary outcomes (VAT area and liver fat content), the double-blind RCT design allows causal inference that berberine does not reduce these outcomes. However, for secondary outcomes (LDL-C, apoB, hs-CRP), the lack of multiplicity adjustment and exploratory nature of analyses mean these results are suggestive but not definitive for causation.
Minor COI
Minor conflicts that may slightly influence the study
The study medication was provided by Yunnan Biovalley Pharmaceutical Co Ltd, but no explicit conflict of interest or funding declarations are reported in the provided text. The trial appears to have independent analysis and safeguards.
Conflict Details
Yunnan Biovalley Pharmaceutical Co Ltd: Manufacturer of study drug
Independent Analysis Safeguards
- Independent statisticians performed final analysis after database lock and unblinding
- Double-blind, placebo-controlled design
- Central online randomization system ensuring allocation concealment
No explicit funding or conflict of interest statements are present in the supplied text. The drug manufacturer's involvement raises a potential conflict, but there is no evidence of influence on study design, analysis, or interpretation.
Key takeaways
- 01
Berberine did not reduce belly fat or liver fat more than placebo.
- 02
However, it did lower some blood fats (LDL cholesterol and apoB) and a marker of inflammation (hs-CRP).
- 03
But these effects were small.
- 04
The lack of effect on fat is clear, but the small improvements in cholesterol and inflammation might be meaningful for heart health, though not proven.
Surprising findings
- Berberine had no effect on visceral fat or liver fat despite prior studies showing benefits in people with diabetes or prediabetes.Previous smaller trials in diabetics found berberine reduced liver fat. This null result in diabetes-free individuals suggests metabolic dysfunction severity matters.
- Berberine reduced LDL-C by -7.72 mg/dL and hs-CRP by -0.072 mg/dL, effects comparable to some statins, but no effect on glucose or insulin resistance.Many expect berberine to improve blood sugar, but in this non-diabetic population, glucose parameters didn't budge.
Practical takeaways
If you have obesity and fatty liver but no diabetes, don't expect berberine to dramatically reduce belly fat or liver fat. Focus on lifestyle interventions like diet and exercise.
Berberine may still offer modest improvements in cholesterol and inflammation, especially if your hs-CRP is high. But these effects are small and not a replacement for statins or other proven therapies.
high confidenceConsider measuring hs-CRP before starting berberine. Those with elevated levels (>0.3 mg/dL) may get more benefit.
This is based on post-hoc analyses and needs validation in dedicated trials.
low confidenceWhy this study matters
Berberine flops on fat reduction
Berberine at 1g/day for 6 months did not significantly reduce visceral adipose tissue area (placebo-adjusted difference 1.38%, P=0.42) or liver fat content (0.87%, P=0.12) compared to placebo in 337 diabetes-free adults with obesity and MASLD.
Many influencers and natural health advocates promote berberine as a natural fat burner. This high-quality RCT challenges that claim for people without diabetes.
Modest lipid and inflammation benefits
Berberine was associated with modest reductions in LDL-C (-7.72 mg/dL), apoB (-3.42 mg/dL), and hs-CRP (-0.072 mg/dL) compared to placebo. These are exploratory findings not adjusted for multiplicity.
Even if it doesn't melt fat, berberine might still offer heart health benefits by lowering atherogenic lipids and inflammation.
High inflammation individuals may benefit more
Post-hoc analyses showed that participants with higher baseline hs-CRP levels experienced larger reductions in LDL-C, apoB, hs-CRP, and even anthropometric measures like BMI and waist circumference.
This suggests that berberine could be personalized—people with elevated inflammation might be 'responders,' while others see little benefit.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers tested a natural supplement called berberine in people with obesity and fatty liver but without diabetes. They gave half the group berberine and half a fake pill (placebo) for 6 months. They used CT scans to measure belly fat and liver fat.
Research results
Berberine did not reduce belly fat or liver fat more than placebo. However, it did lower some blood fats (LDL cholesterol and apoB) and a marker of inflammation (hs-CRP). But these effects were small.
What this means - more context
The lack of effect on fat is clear, but the small improvements in cholesterol and inflammation might be meaningful for heart health, though not proven.
To evaluate the efficacy and safety of berberine in reducing visceral adipose tissue (VAT) area and liver fat content in diabetes-free individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
In a multicenter, double-blind randomized clinical trial, berberine at 1 g/d for 6 months did not significantly reduce VAT area or liver fat content compared with placebo. However, exploratory analyses showed modest reductions in LDL-C, apoB, and hs-CRP. The safety profile was excellent.
Methods Used
Multicenter, double-blind, placebo-controlled RCT; 337 diabetes-free adults with obesity and MASLD (mean age 41.8 years, 65.6% male); randomized to berberine 1 g/d or matching placebo for 6 months; primary outcomes: relative change in VAT area and absolute change in liver fat content by CT; intention-to-treat analysis.
Main Finding
No significant between-group difference in VAT area (adjusted difference 1.38% [97.5% CI, -2.43% to 5.18%]) or liver fat content (0.87% [97.5% CI, -0.39% to 2.13%]). Berberine was associated with modest reductions in LDL-C (-7.72 mg/dL), apoB (-3.42 mg/dL), and hs-CRP (-0.072 mg/dL).
Confidence Level
High for primary null findings (RCT with adequate power, high adherence, and consistent sensitivity analyses). Lower for secondary/exploratory outcomes due to lack of multiplicity adjustment and post-hoc nature.
Study Flags
Red Flags
- •Secondary and exploratory outcomes not adjusted for multiplicity (potential false-positive risk).
- •Post-hoc analyses based on baseline hs-CRP levels may be hypothesis-generating only.
- •4.4% missing data for liver fat content (handled by imputation, but still a limitation).
Surprising Findings
Berberine had no effect on visceral fat or liver fat despite prior studies showing benefits in people with diabetes or prediabetes.
Previous smaller trials in diabetics found berberine reduced liver fat. This null result in diabetes-free individuals suggests metabolic dysfunction severity matters.
Practical Takeaways
If you have obesity and fatty liver but no diabetes, don't expect berberine to dramatically reduce belly fat or liver fat. Focus on lifestyle interventions like diet and exercise.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 578 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
Imagine a test where some people get a real medicine and some get a fake pill that looks the same. Nobody knows who got which, not even the doctors. This kind of test is one of the best ways to see if a medicine really works. In this test, the real medicine did not help reduce belly fat or liver fat, but it seemed to lower bad cholesterol and some signs of swelling in the body. However, those good effects need more checking to be sure.
Minor conflicts detected — such as academic funding or advisory roles. These are common and have a small score impact.
Strengths
- Multicenter, double-blind, placebo-controlled randomized design
- Adequate sample size (n=337) with power calculation
- High medication adherence (90%) and low loss to follow-up
Weaknesses
- Secondary and exploratory outcomes not adjusted for multiplicity, increasing risk of false positives
- Post-hoc subgroup analyses (e.g., by baseline hs-CRP) are exploratory and should be interpreted cautiously
- Single country study limits generalizability
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers tested a natural supplement called berberine in people with obesity and fatty liver but without diabetes. They gave half the group berberine and half a fake pill (placebo) for 6 months. They used CT scans to measure belly fat and liver fat.
Research results
Berberine did not reduce belly fat or liver fat more than placebo. However, it did lower some blood fats (LDL cholesterol and apoB) and a marker of inflammation (hs-CRP). But these effects were small.
What this means - more context
The lack of effect on fat is clear, but the small improvements in cholesterol and inflammation might be meaningful for heart health, though not proven.
To evaluate the efficacy and safety of berberine in reducing visceral adipose tissue (VAT) area and liver fat content in diabetes-free individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
In a multicenter, double-blind randomized clinical trial, berberine at 1 g/d for 6 months did not significantly reduce VAT area or liver fat content compared with placebo. However, exploratory analyses showed modest reductions in LDL-C, apoB, and hs-CRP. The safety profile was excellent.
Methods Used
Multicenter, double-blind, placebo-controlled RCT; 337 diabetes-free adults with obesity and MASLD (mean age 41.8 years, 65.6% male); randomized to berberine 1 g/d or matching placebo for 6 months; primary outcomes: relative change in VAT area and absolute change in liver fat content by CT; intention-to-treat analysis.
Main Finding
No significant between-group difference in VAT area (adjusted difference 1.38% [97.5% CI, -2.43% to 5.18%]) or liver fat content (0.87% [97.5% CI, -0.39% to 2.13%]). Berberine was associated with modest reductions in LDL-C (-7.72 mg/dL), apoB (-3.42 mg/dL), and hs-CRP (-0.072 mg/dL).
Confidence Level
High for primary null findings (RCT with adequate power, high adherence, and consistent sensitivity analyses). Lower for secondary/exploratory outcomes due to lack of multiplicity adjustment and post-hoc nature.
Study Flags
Red Flags
- •Secondary and exploratory outcomes not adjusted for multiplicity (potential false-positive risk).
- •Post-hoc analyses based on baseline hs-CRP levels may be hypothesis-generating only.
- •4.4% missing data for liver fat content (handled by imputation, but still a limitation).
Surprising Findings
Berberine had no effect on visceral fat or liver fat despite prior studies showing benefits in people with diabetes or prediabetes.
Previous smaller trials in diabetics found berberine reduced liver fat. This null result in diabetes-free individuals suggests metabolic dysfunction severity matters.
Practical Takeaways
If you have obesity and fatty liver but no diabetes, don't expect berberine to dramatically reduce belly fat or liver fat. Focus on lifestyle interventions like diet and exercise.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 578 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
Imagine a test where some people get a real medicine and some get a fake pill that looks the same. Nobody knows who got which, not even the doctors. This kind of test is one of the best ways to see if a medicine really works. In this test, the real medicine did not help reduce belly fat or liver fat, but it seemed to lower bad cholesterol and some signs of swelling in the body. However, those good effects need more checking to be sure.
Minor conflicts detected — such as academic funding or advisory roles. These are common and have a small score impact.
Strengths
- Multicenter, double-blind, placebo-controlled randomized design
- Adequate sample size (n=337) with power calculation
- High medication adherence (90%) and low loss to follow-up
Weaknesses
- Secondary and exploratory outcomes not adjusted for multiplicity, increasing risk of false positives
- Post-hoc subgroup analyses (e.g., by baseline hs-CRP) are exploratory and should be interpreted cautiously
- Single country study limits generalizability
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was done carefully: a lot of people took part, the groups were made to be similar, and the people running the test didn't know who got what. This makes the results more trustworthy. But some of the findings (like the cholesterol changes) weren't the main focus, so we should be a little careful until more studies confirm them.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
95 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=337)+16.3/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 578 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. For the primary outcomes (VAT area and liver fat content), the double-blind RCT design allows causal inference that berberine does not reduce these outcomes. However, for secondary outcomes (LDL-C, apoB, hs-CRP), the lack of multiplicity adjustment and exploratory nature of analyses mean these results are suggestive but not definitive for causation.
Minor COI
Minor conflicts that may slightly influence the study
The study medication was provided by Yunnan Biovalley Pharmaceutical Co Ltd, but no explicit conflict of interest or funding declarations are reported in the provided text. The trial appears to have independent analysis and safeguards.
Conflict Details
Yunnan Biovalley Pharmaceutical Co Ltd: Manufacturer of study drug
Independent Analysis Safeguards
- Independent statisticians performed final analysis after database lock and unblinding
- Double-blind, placebo-controlled design
- Central online randomization system ensuring allocation concealment
No explicit funding or conflict of interest statements are present in the supplied text. The drug manufacturer's involvement raises a potential conflict, but there is no evidence of influence on study design, analysis, or interpretation.